+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption



Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption



Antimicrobial Agents and ChemoTherapy 52(6): 2256-2259



Clinical enterococcal resistance to linezolid is defined by the presence of the G2576T mutation. We evaluated the incidence of genetically proven linezolid resistance among vancomycin-resistant Enterococcus faecium strains and linezolid consumption for a possible association. A relationship was found (r(2) = 0.73, P = 0.03) and predicts increasing resistance with current trends of linezolid use.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 031892521

Download citation: RISBibTeXText

PMID: 18391028

DOI: 10.1128/aac.00070-08


Related references

Emergence of increasing linezolid-resistance in enterococci in a post-outbreak situation with vancomycin-resistant Enterococcus faecium. Epidemiology and Infection 136(8): 1131-1133, 2008

Emergence of Increasing Linezolid-Resistance in Enterococci in a Post-Outbreak Situation with Vancomycin-Resistant Enterococcus faecium. Epidemiology and Infection 136(8): 1131-1133, 2008

Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clinical Infectious Diseases 36(11): E146-E148, 2003

Detection of the classical G2576U mutation in linezolid resistant Staphylococcus aureus along with isolation of linezolid resistant Enterococcus faecium from a patient on short-term linezolid therapy: first report from India. Indian Journal of Medical Microbiology 33(1): 21-24, 2016

Novel multiresistance cfr plasmids in linezolid-resistant methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium (VRE) from a hospital outbreak: co-location of cfr and optrA in VRE. Journal of Antimicrobial ChemoTherapy 72(12): 3252-3257, 2017

In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Microbial Drug Resistance 9(4): 389-393, 2003

First report of a linezolid-resistant vancomycin-resistant Enterococcus faecium strain in Greece. Journal of Antimicrobial ChemoTherapy 53(4): 685-686, 2004

Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. New England Journal of Medicine 346(11): 867-869, 2002

Delayed discovery of linezolid-resistant, vancomycin-resistant Enterococcus faecium: lessons learned. Clinical Infectious Diseases 38(1): 155-156, 2004

Novel Inhibitors of Staphyloxanthin Virulence Factor in Comparison with Linezolid and Vancomycin versus Methicillin-Resistant, Linezolid-Resistant, and Vancomycin-Intermediate Staphylococcus aureus Infections in Vivo. Journal of Medicinal Chemistry 60(19): 8145-8159, 2017

Emerging linezolid-resistant, vancomycin resistant Enterococcus faecium from a patient of a haematological unit in Poland. Polish Journal of Microbiology 53(3): 193-196, 2004

Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357(9263): 1179, 2001

First outbreak of linezolid-resistant vancomycin-resistant Enterococcus faecium in an Irish hospital, February to September 2014. Journal of Hospital Infection 91(4): 367-370, 2015

Emergence of linezolid-resistant Enterococcus faecium in the gastrointestinal tract during treatment of vancomycin-resistant enterococcal infections. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 409, 2001

Evaluation of the in vitro activities of quinupristin-dalfopristin , cefepime , linezolid , ampicillin , doxocycline , and vancomycin , alone and/or in combination against vancomycin-resistant Enterococcus faecalis and E faecium , methicillin-resistant Staphylococcus aureus , and glycopeptide intermediate-susceptible S aureus in an in vitro pharmacodynamic infection model IVPM. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 183, 2000